The chemotherapy of head and neck cancer

Anti-Cancer Drugs

Volumn 10, Issue SUPPL. 1, 1999, Pages

  De Mulder, Pieter H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil; Cisplatin; Docetaxel; Head and neck cancer

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; METHOTREXATE;

CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX; LARYNX; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033388014     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199911001-00007     Document Type: Conference Paper

References (19)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA 1995; 45: 8-30.
2. Vokes EE, Weichselbaum RR, Lippman S, et al. Head and neck cancer. N Engl J Med 1993; 328; 184-94.
3. Vokes EE. Head and neck cancer. In: Perry M, ed. The chemotherapy source book. Baltimore, MD: Williams & Willkins 1997: 1083-101.
4. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: a phase II study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521-6.
5. Jacobs C, Lynman G, Velez-Garcia E, et al. A phase III randomized study comparing cisplatin and flourouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-63.
6. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-51.
7. Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end-stage squamous cell carcinoma of the head and neck. Br J Cancer 1990; 61: 311-5.
8. Vokes EE, Wechelbaum RR. Combined modality therapy for head and neck cancer. Principals and Practice of Oncology Update 1993; 6: 1-2.
9. Lefebvre JL, Chevalier D, Lubornski B, et al. Larynx preservation in hypopharynx and lateral epirynx cancer: preliminary results of EORTC randomized phase III trial 2891. J Natl Cancer Inst 1996; 88: 890-88.
10. Posner M, Dreyfuss A, Clark J, et al. Docetaxel for advanced, incurable squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1996; 15: 311 (abstr 0996).
11. Catimel G, Verweij J, Mattijssen V, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7.
12. Couteau C, Leyvrax S, Oulid-Aissa D, et al. A phase II study of docetaxel in squamous cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol 1996; 15: 315 (abstr 889).
13. Schoffski P, Wanders J, Catimel G, et al. A promising regimen for the treatment of squamous cell carcinoma of the head and neck. Docetaxel and cisplatin. Ann Oncol 1998; 7: 79 (suppl 5) (abstr 373P).
14. Janinis J, Papadakou G, Panagos C, et al. A phase II study of combined chemotherapy with docetaxel, cisplatin and 5-fluorouracil (5-FU) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) and nasopharangeal carcinoma (NC). Am Soc Clin Oncol 1997; 16: 402a (abstr 1436).
15. Posner M, Norris O, Colevas A, et al. Phase I/II trial of docetaxel, cisplatin, 5-fluorouracil and leucovorin (TPLF) for curable, locally advanced squamous cell cancer of the head and neck (SCCHN). Am Soc Clin Oncol 1997; 16: 387a (abstr 1380).
16. Colvelas DA, Busse PM, Norris CM, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16: 1331-9.
17. Forastiere A, Glisson B, Murphy B, et al. A phase II study of docetaxel and cisplatin in patients with locally advanced, recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN), not curable by standard therapy. Proc Am Soc Clin Oncol 1998; 17: 399a (abstr 1540).
18. Kienzer HR, Schweiger J, Baur M, et al. Docetaxel (D)/ cisplatin (P) as first-line therapy in head and neck cancer (HNC). Proc Am Soc Clin Oncol 1998; 17: 406a (abstr 1566).
19. Tubiana-Mathieu N, Merrouche Y, Cupissol D, et al. A phase II study of docetaxel (Taxotere) (TXT) in metastatic or recurrent squamous cell carcinoma (SCC) of the head and neck. Proc Am Soc Clin Oncol 1998; 17: 412a (abstr 1587).